ID   PLPL6_HUMAN             Reviewed;        1366 AA.
AC   Q8IY17; A6NGQ0; B4DFB9; B7Z7T2; F5H5K9; J3KQS3; O60859; Q86W58;
AC   Q9UG58;
DT   26-JUN-2007, integrated into UniProtKB/Swiss-Prot.
DT   26-JUN-2007, sequence version 2.
DT   10-MAY-2017, entry version 120.
DE   RecName: Full=Neuropathy target esterase;
DE            EC=3.1.1.5;
DE   AltName: Full=Patatin-like phospholipase domain-containing protein 6;
GN   Name=PNPLA6; Synonyms=NTE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), GLYCOSYLATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=9576844; DOI=10.1042/bj3320001;
RA   Lush M.J., Li Y., Read D.J., Willis A.C., Glynn P.;
RT   "Neuropathy target esterase and a homologous Drosophila
RT   neurodegeneration-associated mutant protein contain a novel domain
RT   conserved from bacteria to man.";
RL   Biochem. J. 332:1-4(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 5), AND VARIANT
RP   PRO-403.
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 34-1366 (ISOFORM 3), AND VARIANTS
RP   PRO-403 AND ARG-1024.
RC   TISSUE=Brain, Duodenum, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 985-1366 (ISOFORMS 1/2).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   FUNCTION.
RX   PubMed=1666291;
RA   Lotti M.;
RT   "The pathogenesis of organophosphate polyneuropathy.";
RL   Crit. Rev. Toxicol. 21:465-487(1991).
RN   [8]
RP   FUNCTION, ENZYME REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=15044461; DOI=10.1074/jbc.M400830200;
RA   Zaccheo O., Dinsdale D., Meacock P.A., Glynn P.;
RT   "Neuropathy target esterase and its yeast homologue degrade
RT   phosphatidylcholine to glycerophosphocholine in living cells.";
RL   J. Biol. Chem. 279:24024-24033(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-345, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-345; THR-352 AND
RP   SER-353, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-345, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-345; SER-353; SER-363
RP   AND SER-411, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   INVOLVEMENT IN BNHS, AND VARIANTS BNHS CYS-1138; CYS-1166 AND
RP   TRP-1350.
RX   PubMed=25033069; DOI=10.1210/jc.2014-1836;
RA   Topaloglu A.K., Lomniczi A., Kretzschmar D., Dissen G.A., Kotan L.D.,
RA   McArdle C.A., Koc A.F., Hamel B.C., Guclu M., Papatya E.D., Eren E.,
RA   Mengen E., Gurbuz F., Cook M., Castellano J.M., Kekil M.B.,
RA   Mungan N.O., Yuksel B., Ojeda S.R.;
RT   "Loss-of-function mutations in PNPLA6 encoding neuropathy target
RT   esterase underlie pubertal failure and neurological deficits in Gordon
RT   Holmes syndrome.";
RL   J. Clin. Endocrinol. Metab. 99:E2067-E2075(2014).
RN   [15]
RP   INVOLVEMENT IN SPG39, AND VARIANTS SPG39 HIS-929 AND VAL-1051.
RX   PubMed=18313024; DOI=10.1016/j.ajhg.2007.12.018;
RA   Rainier S., Bui M., Mark E., Thomas D., Tokarz D., Ming L.,
RA   Delaney C., Richardson R.J., Albers J.W., Matsunami N., Stevens J.,
RA   Coon H., Leppert M., Fink J.K.;
RT   "Neuropathy target esterase gene mutations cause motor neuron
RT   disease.";
RL   Am. J. Hum. Genet. 82:780-785(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-411 AND THR-455, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   TISSUE SPECIFICITY, INVOLVEMENT IN LNMS, INVOLVEMENT IN OMCS, VARIANT
RP   LNMS ARG-717, AND VARIANTS OMCS GLN-1090; ARG-1120; SER-1167 AND
RP   ALA-1206.
RX   PubMed=25480986; DOI=10.1136/jmedgenet-2014-102856;
RA   Hufnagel R.B., Arno G., Hein N.D., Hersheson J., Prasad M.,
RA   Anderson Y., Krueger L.A., Gregory L.C., Stoetzel C., Jaworek T.J.,
RA   Hull S., Li A., Plagnol V., Willen C.M., Morgan T.M., Prows C.A.,
RA   Hegde R.S., Riazuddin S., Grabowski G.A., Richardson R.J.,
RA   Dieterich K., Huang T., Revesz T., Martinez-Barbera J.P., Sisk R.A.,
RA   Jefferies C., Houlden H., Dattani M.T., Fink J.K., Dollfus H.,
RA   Moore A.T., Ahmed Z.M.;
RT   "Neuropathy target esterase impairments cause Oliver-McFarlane and
RT   Laurence-Moon syndromes.";
RL   J. Med. Genet. 52:85-94(2015).
RN   [18]
RP   VARIANTS SPG39 ILE-254 AND GLU-831, VARIANTS BNHS TRP-569; LEU-1036;
RP   ILE-1049; SER-1057; MET-1101 AND LEU-1113, AND VARIANTS GLY-1091 AND
RP   GLY-1353.
RX   PubMed=24355708; DOI=10.1093/brain/awt326;
RA   Synofzik M., Gonzalez M.A., Lourenco C.M., Coutelier M., Haack T.B.,
RA   Rebelo A., Hannequin D., Strom T.M., Prokisch H., Kernstock C.,
RA   Durr A., Schols L., Lima-Martinez M.M., Farooq A., Schule R.,
RA   Stevanin G., Marques W. Jr., Zuchner S.;
RT   "PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes
RT   as part of a broad neurodegenerative spectrum.";
RL   Brain 137:69-77(2014).
CC   -!- FUNCTION: Phospholipase B that deacylates intracellular
CC       phosphatidylcholine (PtdCho), generating glycerophosphocholine
CC       (GroPtdCho). This deacylation occurs at both sn-2 and sn-1
CC       positions of PtdCho. Its specific chemical modification by certain
CC       organophosphorus (OP) compounds leads to distal axonopathy.
CC       {ECO:0000269|PubMed:15044461, ECO:0000269|PubMed:1666291}.
CC   -!- CATALYTIC ACTIVITY: 2-lysophosphatidylcholine + H(2)O =
CC       glycerophosphocholine + a carboxylate.
CC   -!- ENZYME REGULATION: Inhibited by a series a OPs such as mipafox
CC       (MPX), phenyl saligenin phosphate (PSP), phenyl dipentyl
CC       phosphinate (PDPP), diisopropyl fluorophosphate and paraoxon.
CC       {ECO:0000269|PubMed:15044461}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:15044461}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:15044461}; Cytoplasmic side
CC       {ECO:0000269|PubMed:15044461}. Note=Anchored to the cytoplasmic
CC       face of the endoplasmic reticulum by its N-terminal transmembrane
CC       segment. {ECO:0000269|PubMed:15044461}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q8IY17-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IY17-2; Sequence=VSP_026388;
CC       Name=3;
CC         IsoId=Q8IY17-3; Sequence=VSP_026389;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q8IY17-4; Sequence=VSP_046064;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=Q8IY17-5; Sequence=VSP_026388, VSP_046975, VSP_026389;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, placenta, kidney, neuron
CC       and skeletal muscle. Expressed in the developing eye, pituitary
CC       and brain. {ECO:0000269|PubMed:25480986,
CC       ECO:0000269|PubMed:9576844}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:9576844}.
CC   -!- DISEASE: Spastic paraplegia 39, autosomal recessive (SPG39)
CC       [MIM:612020]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness
CC       and spasticity of the lower limbs. Rate of progression and the
CC       severity of symptoms are quite variable. Initial symptoms may
CC       include difficulty with balance, weakness and stiffness in the
CC       legs, muscle spasms, and dragging the toes when walking. In some
CC       forms of the disorder, bladder symptoms (such as incontinence) may
CC       appear, or the weakness and stiffness may spread to other parts of
CC       the body. SPG39 is associated with a motor axonopathy affecting
CC       upper and lower limbs and resulting in progressive wasting of
CC       distal upper and lower extremity muscles.
CC       {ECO:0000269|PubMed:18313024, ECO:0000269|PubMed:24355708}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Boucher-Neuhauser syndrome (BNHS) [MIM:215470]: An
CC       autosomal recessive disorder characterized by spinocerebellar
CC       ataxia, hypogonadotropic hypogonadism, and visual impairment due
CC       to chorioretinal dystrophy. The age at onset is variable, but most
CC       patients develop 1 or more symptoms in the first decade of life.
CC       Chorioretinal dystrophy may not always be present.
CC       {ECO:0000269|PubMed:24355708, ECO:0000269|PubMed:25033069}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Laurence-Moon syndrome (LNMS) [MIM:245800]: An autosomal
CC       recessive syndrome characterized by progressive spinocerebellar
CC       degeneration, spastic paraplegia, mental retardation,
CC       hypogonadism, dwarfism, and chorioretinopathy. Trichomegaly is
CC       absent. {ECO:0000269|PubMed:25480986}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Oliver-McFarlane syndrome (OMCS) [MIM:275400]: A rare
CC       autosomal recessive, congenital syndrome characterized by
CC       trichomegaly, severe chorioretinal atrophy and multiple pituitary
CC       hormone deficiencies. It results in intellectual impairment and
CC       dwarfism, if untreated. Clinical features include hypogonadotropic
CC       hypogonadism during puberty, pigmentary retinal degeneration,
CC       ataxia, spastic paraplegia, and peripheral neuropathy.
CC       {ECO:0000269|PubMed:25480986}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the NTE family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ004832; CAA06164.1; -; mRNA.
DR   EMBL; AK294021; BAG57380.1; -; mRNA.
DR   EMBL; AK302462; BAH13718.1; -; mRNA.
DR   EMBL; AC008878; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC009003; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471139; EAW69029.1; -; Genomic_DNA.
DR   EMBL; BC038229; AAH38229.1; -; mRNA.
DR   EMBL; BC050553; AAH50553.1; -; mRNA.
DR   EMBL; BC051768; AAH51768.1; -; mRNA.
DR   EMBL; AL050362; CAB43674.1; -; mRNA.
DR   CCDS; CCDS32891.1; -. [Q8IY17-2]
DR   CCDS; CCDS54206.1; -. [Q8IY17-4]
DR   CCDS; CCDS54207.1; -. [Q8IY17-5]
DR   CCDS; CCDS59343.1; -. [Q8IY17-3]
DR   RefSeq; NP_001159583.1; NM_001166111.1. [Q8IY17-4]
DR   RefSeq; NP_001159584.1; NM_001166112.1. [Q8IY17-5]
DR   RefSeq; NP_001159585.1; NM_001166113.1. [Q8IY17-2]
DR   RefSeq; NP_001159586.1; NM_001166114.1. [Q8IY17-3]
DR   RefSeq; NP_006693.3; NM_006702.4. [Q8IY17-2]
DR   UniGene; Hs.631863; -.
DR   ProteinModelPortal; Q8IY17; -.
DR   SMR; Q8IY17; -.
DR   BioGrid; 116114; 28.
DR   IntAct; Q8IY17; 18.
DR   STRING; 9606.ENSP00000407509; -.
DR   ChEMBL; CHEMBL2189129; -.
DR   SwissLipids; SLP:000000615; -.
DR   iPTMnet; Q8IY17; -.
DR   PhosphoSitePlus; Q8IY17; -.
DR   BioMuta; PNPLA6; -.
DR   DMDM; 150403921; -.
DR   EPD; Q8IY17; -.
DR   MaxQB; Q8IY17; -.
DR   PaxDb; Q8IY17; -.
DR   PeptideAtlas; Q8IY17; -.
DR   PRIDE; Q8IY17; -.
DR   Ensembl; ENST00000221249; ENSP00000221249; ENSG00000032444. [Q8IY17-2]
DR   Ensembl; ENST00000414982; ENSP00000407509; ENSG00000032444. [Q8IY17-4]
DR   Ensembl; ENST00000450331; ENSP00000394348; ENSG00000032444. [Q8IY17-2]
DR   Ensembl; ENST00000545201; ENSP00000443323; ENSG00000032444. [Q8IY17-5]
DR   Ensembl; ENST00000600737; ENSP00000473211; ENSG00000032444. [Q8IY17-3]
DR   GeneID; 10908; -.
DR   KEGG; hsa:10908; -.
DR   UCSC; uc002mgq.3; human. [Q8IY17-1]
DR   CTD; 10908; -.
DR   DisGeNET; 10908; -.
DR   GeneCards; PNPLA6; -.
DR   HGNC; HGNC:16268; PNPLA6.
DR   HPA; HPA007522; -.
DR   MalaCards; PNPLA6; -.
DR   MIM; 215470; phenotype.
DR   MIM; 245800; phenotype.
DR   MIM; 275400; phenotype.
DR   MIM; 603197; gene.
DR   MIM; 612020; phenotype.
DR   neXtProt; NX_Q8IY17; -.
DR   OpenTargets; ENSG00000032444; -.
DR   Orphanet; 1180; Ataxia - hypogonadism - choroidal dystrophy.
DR   Orphanet; 139480; Autosomal recessive spastic paraplegia type 39.
DR   Orphanet; 1173; Cerebellar ataxia - hypogonadism.
DR   PharmGKB; PA145148268; -.
DR   eggNOG; KOG2968; Eukaryota.
DR   eggNOG; COG0664; LUCA.
DR   eggNOG; COG1752; LUCA.
DR   GeneTree; ENSGT00390000002533; -.
DR   HOGENOM; HOG000016081; -.
DR   HOVERGEN; HBG053067; -.
DR   InParanoid; Q8IY17; -.
DR   KO; K14676; -.
DR   OMA; IRMSAFV; -.
DR   OrthoDB; EOG091G00XM; -.
DR   PhylomeDB; Q8IY17; -.
DR   TreeFam; TF300519; -.
DR   Reactome; R-HSA-6814848; Glycerophospholipid catabolism.
DR   ChiTaRS; PNPLA6; human.
DR   GeneWiki; Neuropathy_target_esterase; -.
DR   GenomeRNAi; 10908; -.
DR   PRO; PR:Q8IY17; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000032444; -.
DR   CleanEx; HS_PNPLA6; -.
DR   ExpressionAtlas; Q8IY17; baseline and differential.
DR   Genevisible; Q8IY17; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0004622; F:lysophospholipase activity; EXP:Reactome.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0009887; P:animal organ morphogenesis; IEA:Ensembl.
DR   GO; GO:0032502; P:developmental process; IBA:GO_Central.
DR   GO; GO:0046475; P:glycerophospholipid catabolic process; TAS:Reactome.
DR   GO; GO:0046470; P:phosphatidylcholine metabolic process; IEA:InterPro.
DR   Gene3D; 2.60.120.10; -; 3.
DR   InterPro; IPR016035; Acyl_Trfase/lysoPLipase.
DR   InterPro; IPR018490; cNMP-bd-like.
DR   InterPro; IPR000595; cNMP-bd_dom.
DR   InterPro; IPR001423; LysoPLipase_patatin_CS.
DR   InterPro; IPR002641; PNPLA_dom.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   Pfam; PF00027; cNMP_binding; 3.
DR   Pfam; PF01734; Patatin; 1.
DR   SMART; SM00100; cNMP; 3.
DR   SUPFAM; SSF51206; SSF51206; 3.
DR   SUPFAM; SSF52151; SSF52151; 1.
DR   PROSITE; PS50042; CNMP_BINDING_3; 3.
DR   PROSITE; PS51635; PNPLA; 1.
DR   PROSITE; PS01237; UPF0028; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation; Dwarfism;
KW   Endoplasmic reticulum; Glycoprotein; Hereditary spastic paraplegia;
KW   Hydrolase; Hypogonadotropic hypogonadism; Lipid degradation;
KW   Lipid metabolism; Membrane; Mental retardation; Neurodegeneration;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Retinitis pigmentosa; Transmembrane; Transmembrane helix.
FT   CHAIN         1   1366       Neuropathy target esterase.
FT                                /FTId=PRO_0000292199.
FT   TOPO_DOM      1     50       Lumenal. {ECO:0000255}.
FT   TRANSMEM     51     71       Helical. {ECO:0000255}.
FT   TOPO_DOM     72   1366       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      972   1138       PNPLA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   NP_BIND     186    313       cNMP 1.
FT   NP_BIND     502    624       cNMP 2.
FT   NP_BIND     620    740       cNMP 3.
FT   MOTIF       976    981       GXGXXG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF      1003   1007       GXSXG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF      1125   1127       DGA/G. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   ACT_SITE   1005   1005       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   ACT_SITE   1125   1125       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOD_RES     345    345       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     352    352       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     353    353       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     363    363       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     411    411       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     455    455       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     11     11       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1     48       MGTSSHGLATNSSGAKVAERDGFQDVLAPGEGSAGRICGAQ
FT                                PVPFVPQ -> MEAPLQTGM (in isoform 2 and
FT                                isoform 5). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9576844}.
FT                                /FTId=VSP_026388.
FT   VAR_SEQ       1      1       M -> MEAPLQTGMM (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046064.
FT   VAR_SEQ     511    536       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046975.
FT   VAR_SEQ     754    754       Missing (in isoform 3 and isoform 5).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_026389.
FT   VARIANT     254    254       V -> I (in SPG39).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071091.
FT   VARIANT     403    403       A -> P (in dbSNP:rs17854645).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_032949.
FT   VARIANT     569    569       G -> W (in BNHS).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071092.
FT   VARIANT     717    717       G -> R (in LNMS).
FT                                {ECO:0000269|PubMed:25480986}.
FT                                /FTId=VAR_073409.
FT   VARIANT     831    831       G -> E (in SPG39).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071093.
FT   VARIANT     929    929       R -> H (in SPG39).
FT                                {ECO:0000269|PubMed:18313024}.
FT                                /FTId=VAR_044409.
FT   VARIANT    1024   1024       K -> R (in dbSNP:rs17854647).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_032950.
FT   VARIANT    1036   1036       S -> L (in BNHS).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071094.
FT   VARIANT    1049   1049       T -> I (in BNHS).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071095.
FT   VARIANT    1051   1051       M -> V (in SPG39).
FT                                {ECO:0000269|PubMed:18313024}.
FT                                /FTId=VAR_044410.
FT   VARIANT    1057   1057       F -> S (in BNHS).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071096.
FT   VARIANT    1090   1090       R -> Q (in OMCS).
FT                                {ECO:0000269|PubMed:25480986}.
FT                                /FTId=VAR_073410.
FT   VARIANT    1091   1091       V -> G (found in a patient with sporadic
FT                                ataxia and BNHS; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071097.
FT   VARIANT    1101   1101       V -> M (in BNHS).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071098.
FT   VARIANT    1113   1113       P -> L (in BNHS).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071099.
FT   VARIANT    1120   1120       G -> R (in OMCS).
FT                                {ECO:0000269|PubMed:25480986}.
FT                                /FTId=VAR_073411.
FT   VARIANT    1138   1138       R -> C (in BNHS).
FT                                {ECO:0000269|PubMed:25033069}.
FT                                /FTId=VAR_073412.
FT   VARIANT    1166   1166       S -> C (in BNHS).
FT                                {ECO:0000269|PubMed:25033069}.
FT                                /FTId=VAR_073413.
FT   VARIANT    1167   1167       G -> S (in OMCS).
FT                                {ECO:0000269|PubMed:25480986}.
FT                                /FTId=VAR_073414.
FT   VARIANT    1206   1206       V -> A (in OMCS).
FT                                {ECO:0000269|PubMed:25480986}.
FT                                /FTId=VAR_073415.
FT   VARIANT    1350   1350       R -> W (in BNHS).
FT                                {ECO:0000269|PubMed:25033069}.
FT                                /FTId=VAR_073416.
FT   VARIANT    1353   1353       R -> G (found in a patient with Gordon-
FT                                Holmes syndrome; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24355708}.
FT                                /FTId=VAR_071100.
FT   CONFLICT     34     37       AGRI -> TRPV (in Ref. 5; AAH38229).
FT                                {ECO:0000305}.
FT   CONFLICT    639    639       T -> A (in Ref. 2; BAG57380).
FT                                {ECO:0000305}.
FT   CONFLICT    705    705       A -> T (in Ref. 5; AAH38229).
FT                                {ECO:0000305}.
FT   CONFLICT    985    985       I -> W (in Ref. 6; CAB43674).
FT                                {ECO:0000305}.
FT   CONFLICT   1169   1169       W -> V (in Ref. 6; CAB43674).
FT                                {ECO:0000305}.
FT   CONFLICT   1287   1287       E -> G (in Ref. 6; CAB43674).
FT                                {ECO:0000305}.
FT   CONFLICT   1293   1293       E -> K (in Ref. 3; BAH13718).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1366 AA;  149995 MW;  705E9A4E2195C887 CRC64;
     MGTSSHGLAT NSSGAKVAER DGFQDVLAPG EGSAGRICGA QPVPFVPQVL GVMIGAGVAV
     VVTAVLILLV VRRLRVPKTP APDGPRYRFR KRDKVLFYGR KIMRKVSQST SSLVDTSVSA
     TSRPRMRKKL KMLNIAKKIL RIQKETPTLQ RKEPPPAVLE ADLTEGDLAN SHLPSEVLYM
     LKNVRVLGHF EKPLFLELCR HMVFQRLGQG DYVFRPGQPD ASIYVVQDGL LELCLPGPDG
     KECVVKEVVP GDSVNSLLSI LDVITGHQHP QRTVSARAAR DSTVLRLPVE AFSAVFTKYP
     ESLVRVVQII MVRLQRVTFL ALHNYLGLTN ELFSHEIQPL RLFPSPGLPT RTSPVRGSKR
     MVSTSATDEP RETPGRPPDP TGAPLPGPTG DPVKPTSLET PSAPLLSRCV SMPGDISGLQ
     GGPRSDFDMA YERGRISVSL QEEASGGSLA APARTPTQEP REQPAGACEY SYCEDESATG
     GCPFGPYQGR QTSSIFEAAK QELAKLMRIE DPSLLNSRVL LHHAKAGTII ARQGDQDVSL
     HFVLWGCLHV YQRMIDKAED VCLFVAQPGE LVGQLAVLTG EPLIFTLRAQ RDCTFLRISK
     SDFYEIMRAQ PSVVLSAAHT VAARMSPFVR QMDFAIDWTA VEAGRALYRQ GDRSDCTYIV
     LNGRLRSVIQ RGSGKKELVG EYGRGDLIGV VEALTRQPRA TTVHAVRDTE LAKLPEGTLG
     HIKRRYPQVV TRLIHLLSQK ILGNLQQLQG PFPAGSGLGV PPHSELTNPA SNLATVAILP
     VCAEVPMVAF TLELQHALQA IGPTLLLNSD IIRARLGASA LDSIQEFRLS GWLAQQEDAH
     RIVLYQTDAS LTPWTVRCLR QADCILIVGL GDQEPTLGQL EQMLENTAVR ALKQLVLLHR
     EEGAGPTRTV EWLNMRSWCS GHLHLRCPRR LFSRRSPAKL HELYEKVFSR RADRHSDFSR
     LARVLTGNTI ALVLGGGGAR GCSHIGVLKA LEEAGVPVDL VGGTSIGSFI GALYAEERSA
     SRTKQRAREW AKSMTSVLEP VLDLTYPVTS MFTGSAFNRS IHRVFQDKQI EDLWLPYFNV
     TTDITASAMR VHKDGSLWRY VRASMTLSGY LPPLCDPKDG HLLMDGGYIN NLPADIARSM
     GAKTVIAIDV GSQDETDLST YGDSLSGWWL LWKRLNPWAD KVKVPDMAEI QSRLAYVSCV
     RQLEVVKSSS YCEYLRPPID CFKTMDFGKF DQIYDVGYQY GKAVFGGWSR GNVIEKMLTD
     RRSTDLNESR RADVLAFPSS GFTDLAEIVS RIEPPTSYVS DGCADGEESD CLTEYEEDAG
     PDCSRDEGGS PEGASPSTAS EMEEEKSILR QRRCLPQEPP GSATDA
//
